The content on this site is intended for healthcare professionals only
Prof Joseph Gligorov speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about adjuvant anti-HER2-positive treatment in HER2-positive breast cancer and what to do after a patient has received a pathologic complete response (pCR).
He explains that this is an ongoing debate, as there is no clinical trial addressing this issue, but believes that dual HER2 blockade with pertuzumab should still be continued if the patient has lymph node-positive disease.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer
EAU 2024: Bladder cancer latest
Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
OncoAlert Round Up for August 25th - 31st, 2023
